Using a cohort of 42 RCC patients treated with anti-PD-1 or anti-PD-L1 (nivolumab, atezolizumab, avelumab), Bergerot et al. reported that combined overweight plus obesity had a trending but non-significant detrimental effect on survival (19.9 months for overweight plus obesity vs 23.6 months in normal weight, p = 0.26) (44) (Table 2). Here, PDCD1 is linked to Obesity.